Display Settings:

Format

Send to:

Choose Destination
Curr Allergy Asthma Rep. 2011 Feb;11(1):7-11. doi: 10.1007/s11882-010-0153-8.

Interleukin-33 in asthma: how big of a role does it play?

Author information

  • 1Asthma and Allergic Disease Center, Box 801355, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA. lb4m@virginia.edu

Abstract

In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.

PMID:
20931364
[PubMed - indexed for MEDLINE]
PMCID:
PMC3068600
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk